36P Exploring the Role of Soluble B7-H3 (Sb7-H3) As a Biomarker to Predict the Clinical Benefit And/or the Occurrence of Immune Related Adverse Events (iraes) in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors (Icis)